Босния и Герцеговина - хорватский - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

novartis ba d.o.o. - filgrastim - rastvor za injekciju /infuziju u napunjenoj šprici - 300 µg/0.5 ml - 0,5 ml rastvora za injekciju ili infuziju sadrži: 300 mcg (30 mu) rekombinantni filgrastim

Босния и Герцеговина - хорватский - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

novartis ba d.o.o. - filgrastim - rastvor za injekciju /infuziju u napunjenoj šprici - 300 µg/0.5 ml - 0,5 ml rastvora za injekciju ili infuziju sadrži 300 mcg (30 mu) rekombinantni filgrastim

Босния и Герцеговина - хорватский - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

merck sharp & dohme bh d.o.o. - pembrolizumab - prašak za koncentrat za rastvor za infuziju - 50 mg/1 bočica - 1 bočica praška za kocentrat za rastvor za infuziju sadrži: 50 mg pembrolizumaba

Босния и Герцеговина - хорватский - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

merck sharp & dohme bh d.o.o. - pembrolizumab - koncentrat za rastvor za infuziju - 25 mg/1 ml - 1 bočica sa 4 ml koncentrata za rastvor za infuziju sadrži: 100 mg pembrolizumaba

Европейский союз - хорватский - EMA (European Medicines Agency)

nova laboratories ireland limited - azathioprine - odbacivanje transplantata - imunosupresivi - jayempi is indicated in combination with other immunosuppressive agents for the prophylaxis of transplant rejection in patients receiving allogenic kidney, liver, heart, lung or pancreas transplants. azathioprine is indicated in immunosuppressive regimens as an adjunct to immunosuppressive agents that form the mainstay of treatment (basis immunosuppression). jayempi is used as an immunosuppressant antimetabolite either alone or, more commonly, in combination with other agents (usually corticosteroids) and/ or procedures which influence the immune response. jayempi is indicated in patients who are intolerant to glucocorticosteroids or if the therapeutic response is inadequate despite treatment with high doses of glucocorticosteroids, in the following diseases:severe active rheumatoid arthritis (chronic polyarthritis) that cannot be kept under control by less toxic agents (disease-modifying anti-rheumatic -medicinal products – dmards)auto-immune hepatitis systemic lupus erythematosusdermatomyositispolyarteritis nodosapemphigus vulgaris and bullous pemphigoidbehçet’s diseaserefractory auto-immune haemolytic anaemia, caused by warm igg antibodieschronic refractory idiopathic thrombocytopenic purpurajayempi is used for the treatment of moderately severe to severe forms of chronic inflammatory bowel disease (ibd) (crohn’s disease or ulcerative colitis) in patients in whom glucocorticosteroid therapy is necessary, but where glucocorticosteroids are not tolerated, or in whom the disease is untreatable with other common means of first choice. it is also indicated in adult patients in relapsing multiple sclerosis, if an immunomodulatory therapy is indicated but beta interferon therapy is not possible, or a stable course has been achieved with previous treatment with azathioprine. 3jayempi is indicated for the treatment of generalised myasthenia gravis. depending on the severity of the disease, jayempi should be given in combination with glucocorticosteroids because of slow onset of action at the beginning of treatment and the glucocorticosteroid dose should be gradually reduced after several months of treatment.

Европейский союз - хорватский - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - idecabtagene vicleucel - multiple myeloma; neoplasms; cancer; neoplasms, plasma cell; hemostatic disorders; vascular diseases; cardiovascular diseases; paraproteinemias; blood protein disorders; hematologic diseases; hemic and lymphatic diseases; hemorrhagic disorders; infectious mononucleosis; lymphoproliferative disorders; immunoproliferative disorders; immune system diseases - antineoplastična sredstva - abecma is indicated for the treatment of adult patients with relapsed and refractory multiple myeloma who have received at least three prior therapies, including an immunomodulatory agent, a proteasome inhibitor and an anti cd38 antibody and have demonstrated disease progression on the last therapy.

Босния и Герцеговина - хорватский - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

merck sharp & dohme bh d.o.o. - pembrolizumab - koncentrat za rastvor za infuziju - 25 mg/1 ml - 1 bočica sa 4 ml koncentrata za rastvor za infuziju sadrži: 100 mg pembrolizumaba

Босния и Герцеговина - хорватский - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

delta pharma d.o.o. sarajevo - filgrastim - rastvor za injekciju /infuziju u napunjenoj šprici - 300 µg/0.5 ml - 1 napunjena šprica od 0,5 ml sadrži 30 miliona jedinica (30 mu/300 mikrograma) filgrastima (rmethugcsf, rekonbinantni metionilizirani faktor stimulacije rasta granulocita)

Хорватия - хорватский - HALMED (Agencija za lijekove i medicinske proizvode)

medical developments ned b.v., strawinskylaan 411, wtc tower a, amsterdam, nizozemska - metoksifluran - para inhalata, tekućina - 99,9%,3 ml - urbroj: jedna bočica sadrži 3 ml metoksiflurana (99,9%)

Хорватия - хорватский - HALMED (Agencija za lijekove i medicinske proizvode)

baxter d.o.o., letališka cesta 29a, ljubljana, slovenija - sevofluran - para inhalata, tekućina - 100 % - urbroj: 1 boca od 250 ml sadrži 100 % sevoflurana